Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Genetics Completes $27.3M Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Infectious disease test development firm Atlas Genetics announced this week the completion of a Series B financing round that raised £16.9 million ($27.3 million).

The funds, to be drawn down over three years, will be used to accelerate the launch of Atlas' Velox point-of-care products for chlamydia and gonorrhea, as well as for the development of other tests and to expand the immunoassay capability of the Velox system, the Bristol, UK-based company said.

Velox is a molecular diagnostic platform that runs assays for the detection of DNA and RNA using electrochemistry. According to Atlas' website, its single-use test cartridges contain all the reagents that are needed to extract DNA, amplify a specific sequence, and detect the target.

The technology uses target-specific probes labeled with an electronic ferrocene tag. After the pathogen DNA is copied, the probe is added, which then binds with the pathogen DNA. This, in combination with a specific enzyme, makes detection of an electronic signal possible.

Leading the financing round was new investor Novartis Venture Funds and existing investor Consort Medical. Other new investors included Life Science Partners, BB Biotech Ventures, and Johnson & Johnson Development.

In February, Atlas raised £1.5 million when Consort Medical took a 20 percent stake in the company. Spun out of Bath University, it raised about $4.1 million in 2008.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.